GleamWall
中文EN

MAIA MAIA Biotechnology, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1878313 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.4%
TTM EPS YoY36.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-341.5%
ROA-148.3%
ROIC (approx.)-296.5%
Asset turnover—

Leverage & solvency

Liabilities / assets33.6%
Debt / equity0.00x
Current ratio3.41x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio1.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$5.34M$5.64M$43,651-$12.21M$6.36M$3.11M$3.20M$2.97M
SG&A expense$2.69M$2.68M$3.42M$2.44M$3.00M$2.06M$2.23M$2.04M
Operating income-$8.02M-$8.32M-$6.95M-$4.32M-$9.36M-$5.17M-$5.43M-$5.00M
Interest expense———————-$28
Income tax——$339$2,000$0$0$0$2,000
Net income-$7.18M-$7.94M-$6.37M-$3.63M-$8.90M-$5.35M-$4.52M-$3.57M
EPS (basic)-0.12-0.13-0.14—-0.27-0.18-0.16—
EPS (diluted)-0.12-0.13-0.14—-0.27-0.18-0.16—
Weighted avg. shares (diluted)60.86M60.79M45.21M—33.20M30.30M27.70M—
Balance sheet
Cash & equivalents$0$0$0$0$0$0$0$0
Current assets$22.10M$28.24M$35.32M$9.70M$11.75M$11.04M$11.86M$10.15M
Total assets$22.10M$28.24M$35.32M$9.70M$11.78M$11.05M$11.86M$10.16M
Current liabilities$6.47M$6.26M$6.32M$5.84M$9.99M$5.04M$5.06M$3.83M
Total liabilities$7.43M$7.57M$7.56M$7.33M$11.74M$7.17M$6.92M$6.52M
Shareholders' equity$14.67M$20.68M$27.76M$2.38M$41,670$3.88M$4.94M$3.63M
Shares outstanding61.74M60.82M60.67M38.62M34.45M31.82M29.59M26.16M
Cash flow statement
Operating cash flow-$6.31M-$6.75M-$5.31M-$7.02M-$3.49M-$4.14M-$4.20M-$3.91M
Financing cash flow$0-$65,000$31.05M$4.80M$4.23M$3.41M$5.46M$4.85M
Stock-based compensation$881,757$723,915$650,024$810,796$646,900$802,484$371,472$693,443

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.